Hepatitis C Virus Therapy
Researchers from National Institute of Diabetes and Digestive and Kidney Diseases report recent findings in hepatitis C virus therapy
Published in Gastroenterology Week, June 18th, 2007
Investigators publish new data in the report "Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy." According to a study from the United States, "Error catastrophe from an increase in mutation rate may be a possible mechanism of action of ribavirin in chronic hepatitis C (CHC). We sought to evaluate the mutagenic potential of ribavirin in vivo and to determine if conserved regions of hepatitis C virus (HCV) NS5B are mutated during ribavirin therapy."
"Thirty-one patients with CHC genotype 1 who participated in a randomized, placebo-controlled trial of ribavirin for 48 weeks were studied. After 48 weeks, patients on...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
More Articles from Gastroenterology Week
- Angiology
FDA Approves Ostial Pro Stent Positioning System - Cardiology
Advanced Hybrid Cardiac Diagnostic Imaging System - Colon Cancer
Exploring better ways to determine when to change the course of treatment - Colon Cancer
Gender Impacts Colorectal Cancer Progression - Colon Cancer
Taking folic acid does not reduce risk of precancerous colon tumors - Diaphragmatic Hernia
Understanding and treating congenital diaphragmatic hernia - More from this issue of Gastroenterology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
